mRNA |
JW-480 |
CTRPv2 |
pan-cancer |
AAC |
-0.032 |
0.4 |
mRNA |
GSK2126458 |
GDSC1000 |
pan-cancer |
AAC |
-0.027 |
0.4 |
mRNA |
Erlotinib |
CTRPv2 |
pan-cancer |
AAC |
0.029 |
0.4 |
mRNA |
CHEMBL1222381 |
CTRPv2 |
pan-cancer |
AAC |
0.028 |
0.4 |
mRNA |
BRD-A02303741:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.03 |
0.4 |
mRNA |
ISOX:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.029 |
0.4 |
mRNA |
AZD6244 |
CTRPv2 |
pan-cancer |
AAC |
-0.029 |
0.4 |
mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.031 |
0.4 |
mRNA |
FH535 |
GDSC1000 |
pan-cancer |
AAC |
0.028 |
0.4 |
mRNA |
semagacestat |
CTRPv2 |
pan-cancer |
AAC |
-0.03 |
0.4 |